open access
Vol 27, No 4 (2020)
Editorial comment — Clinical cardiology
Submitted: 2020-04-23
Accepted: 2020-05-12
Published online: 2020-05-14
Get Citation
Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm
1, 2, 3
Affiliations- Department of Internal Medicine and Cardiology, Medical University of Warsaw,
- First Department of Cardiology, Medical University of Gdansk, Gdańsk, Poland.
- Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Center of Postgraduate Education Medical, European Health Center Otwock, Poland
open access
Vol 27, No 4 (2020)
Editorial comment — Clinical cardiology
Submitted: 2020-04-23
Accepted: 2020-05-12
Published online: 2020-05-14
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Direct oral anticoagulants in cancer-associated venous thromboembolism: It is high time for a change of therapeutic paradigm
Journal
Issue
Pages
347-349
Published online
2020-05-14
Page views
844
Article views/downloads
807
DOI
Pubmed
Bibliographic record
Cardiol J 2020;27(4):347-349.
Authors
Justyna Domienik-Karłowicz
Miłosz Jaguszewski
Marcin Kurzyna
References (8)- Agnelli G, Becattini C, Meyer G, et al. Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020; 382(17): 1599–1607.
- Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009; 27(29): 4902–4911.
- Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458–464.
- Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012; 9(7): e1001275.
- Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146–153.
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020; 41(4): 543–603.
- Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
- Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.
